The Committee discussed appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving testicular function, including spermatogenesis.
Back to All Events
Earlier Event: November 17
Blood Products Advisory Committee
Later Event: February 9
Advisory Committee on Heritable Disorders in Newborns and Children